HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Joanna Kitlinska Selected Research

Neuropeptide Y

5/2022Publisher Correction: Hypoxia-activated neuropeptide Y/Y5 receptor/RhoA pathway triggers chromosomal instability and bone metastasis in Ewing sarcoma.
1/2022Hypoxia-activated neuropeptide Y/Y5 receptor/RhoA pathway triggers chromosomal instability and bone metastasis in Ewing sarcoma.
1/2020Neuropeptide Y/Y5 Receptor Pathway Stimulates Neuroblastoma Cell Motility Through RhoA Activation.
11/2016Neuropeptide Y as a Biomarker and Therapeutic Target for Neuroblastoma.
2/2016Elevated levels of neuropeptide Y in preeclampsia: A pilot study implicating a role for stress in pathogenesis of the disease.
2/2016Neuropeptide Y (NPY) in tumor growth and progression: Lessons learned from pediatric oncology.
3/2015High neuropeptide Y release associates with Ewing sarcoma bone dissemination - in vivo model of site-specific metastases.
12/2013Hypoxia shifts activity of neuropeptide Y in Ewing sarcoma from growth-inhibitory to growth-promoting effects.
6/2013Platelet neuropeptide Y is critical for ischemic revascularization in mice.
8/2011Dipeptidyl peptidases as survival factors in Ewing sarcoma family of tumors: implications for tumor biology and therapy.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Joanna Kitlinska Research Topics

Disease

11Neoplasms (Cancer)
01/2020 - 03/2005
7Ewing Sarcoma (Sarcoma, Ewing)
05/2022 - 01/2006
4Hypoxia (Hypoxemia)
05/2022 - 12/2013
4Neuroblastoma
01/2020 - 01/2007
3Neoplasm Metastasis (Metastasis)
05/2022 - 03/2015
2Chromosomal Instability (Chromosome Stability)
05/2022 - 01/2022
2Ischemia
06/2013 - 06/2003
2Neural crest tumor
01/2007 - 03/2005
2Vascular Remodeling
09/2004 - 01/2003
1Polyploidy
01/2022
1Disease Progression
11/2016
1Pre-Eclampsia (Preeclampsia)
02/2016
1Pheochromocytoma
01/2007
1Hypertension (High Blood Pressure)
09/2004
1Peripheral Vascular Diseases (Peripheral Vascular Disease)
09/2004
1Cardiovascular Diseases (Cardiovascular Disease)
09/2004
1Atherosclerosis
09/2004

Drug/Important Bio-Agent (IBA)

15Neuropeptide YIBA
05/2022 - 09/2004
5Peptides (Polypeptides)IBA
02/2016 - 03/2005
4Neurotransmitter Agents (Neurotransmitter)IBA
11/2016 - 01/2010
4Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA
02/2016 - 01/2003
3EWS-FLI fusion proteinIBA
03/2015 - 08/2011
2Proteins (Proteins, Gene)FDA Link
03/2015 - 12/2013
1neuropeptide Y5 receptorIBA
01/2022
1rho-Associated KinasesIBA
01/2020
1Y 27632IBA
01/2020
1RNA (Ribonucleic Acid)IBA
11/2016
1Biomarkers (Surrogate Marker)IBA
11/2016
1A-factor (Streptomyces)IBA
02/2016
1EnzymesIBA
12/2013
1LigandsIBA
12/2013
1Aldehyde DehydrogenaseIBA
12/2013
1Dipeptidyl-Peptidases and Tripeptidyl-PeptidasesIBA
08/2011
1dipalmitoylphosphatidylserineIBA
08/2011
1Transcription Factors (Transcription Factor)IBA
08/2011
1Epinephrine (Adrenaline)FDA LinkGeneric
01/2010
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2010
1CatecholaminesIBA
01/2010
1Adrenergic Agents (Adrenergic Drugs)IBA
01/2010
1Norepinephrine (Noradrenaline)FDA LinkGeneric
01/2010
1NeuropeptidesIBA
01/2010
1Dopamine (Intropin)FDA LinkGeneric
01/2010
1Pharmaceutical PreparationsIBA
09/2004
1Peptide Hydrolases (Proteases)FDA Link
06/2003

Therapy/Procedure

5Therapeutics
01/2020 - 02/2007
1Drug Therapy (Chemotherapy)
01/2022
1Sympathectomy (Sympathectomies)
06/2003